Allison Unveils New Brand Identity to Reflect Agency’s Evolution
After more than two decades of remarkable growth and evolution, Allison (fka Allison+Partners) is excited to unveil its new brand identity, complete with a new name, logo, website and visual identity. The rebranding effort reflects the agency's transformation from its origin as a traditional PR firm focused on earned media to a modern integrated marketing and communications powerhouse with a global presence.
"Today marks a significant milestone in our history,” says Scott Allison, global chairman and CEO of Allison. “The unveiling of our new brand identity represents not just a change in name and logo, but a bold declaration of our commitment to shaping the future of integrated marketing and communications. We have evolved alongside the industry, embracing innovation and expanding our global footprint. This rebranding is a testament to our team's dedication to excellence, creativity, and the relentless pursuit of solutions that drive meaningful impact for our clients. With Allison, we are poised to lead the way in a new era of communications."
Why Rebrand? Why Now?
Over the past 22 years, Allison has undergone a remarkable evolution, expanding its services, client portfolio and talent base to encompass a diverse range of expertise, from to creative solutions. The agency also saw significant growth in the number of global assignments —with seven of its top 10 clients now represented across multiple markets—and an enhanced client roster of global brands, such as AB InBev, GE Appliances, Hewlett Packard Enterprise, IHG, Kyndryl and Revlon. This rebranding initiative is a response to the need for a refreshed brand identity that aligns with the agency's current and future trajectory, while highlighting its unique culture, global reach, integrated capabilities and forward-thinking approach. Visit the new website at www.allisonworldwide.com to explore the refreshed brand identity and learn more about Allison's innovative solutions.
Solving Fragmentation and Embracing Innovation
The rebranding also aims to address the challenge of fragmentation that has naturally occurred as the agency has grown and the marketing landscape has evolved, potentially diluting or blurring the agency's points of differentiation. By simplifying and unifying the brand story, Allison will better convey its ability to solve complex business challenges, attract top talent, and provide integrated marketing and communications on a global scale. The new brand identity not only celebrates the agency's growth but also positions it as a driver of the industry's future innovations.
A Fresh and Modern Identity Built In-House
Allison’s Brand and Engagement Strategy Team led the new brand identity, using its approach to research, strategy and branding for clients called V.I.T.A.L, which is a framework that helps companies understand and express a brand’s humanity (and therefore build engagement). The new brand features a sleek and modern logo that signifies the agency's evolution and commitment to innovation. The cutout in the I represent the agency’s vision of always moving forward with innovation and a commitment to excellence. The name change to "Allison" showcases a more inclusive and contemporary identity, while paying homage to the agency's founders and their values. The removal of "+Partners" reflects the team-oriented approach Allison has always been known for, emphasizing the agency's focus on inclusion, unity and diversity.
Forward-Looking Vision
With the rebrand, Allison sets its sights on its evolution to a fully integrated marketing and communications consultancy. Its Marketing Innovation Team offers integrated marketing, brand engagement strategies, performance marketing, creative, Storytelling Studio, and research and analytics functions, while its Allison Advisory team helps the C-suite accelerate growth by finding and optimizing the intersection of business goals, customer needs, regulatory environments and employee experience. The agency plans to bolster its creative capabilities, achieve rapid growth through targeted acquisitions, and continue to expand its service offerings beyond its PR roots driving innovation through a deep expertise in data and technology.
Brand Manifesto, Mission, Vision, and Purpose
The new brand manifesto, Always Forward, speaks to the agency's dedication to agility, innovation and forward momentum. The mission underscores that it's all about the work—unlocking insights, inspiring innovation and building meaningful connections. The vision and purpose highlight Allison's commitment to a limitless environment where everyone can build, create and grow, while using creativity to drive positive change and business success.
Agency Solutions
At the heart of the rebrand is a profound shift towards enhanced client offerings. Every solution is thoughtfully crafted to address the unique challenges our clients face in today's ever-changing global marketplace. By immersing ourselves in our clients' issues, Allison transcends the boundaries of conventional marketing, emerging as problem solvers and trusted partners. With this new approach, Allison emphasizes its ability to drive awareness and demand, increase cultural relevance, build and protect reputations, transform brands, and elevate business performance for clients across the globe. The solutions are not just services; they are pathways to success, strategies to create change and blueprints for navigating the dynamic marketing landscape.
With this rebrand, Allison is poised to embark on an exciting new chapter, while respecting the legacy of growth that has made it one of the greatest success stories in the industry over the past 22 years, showcasing its evolution, innovation and commitment to always move forward. The new brand identity captures the agency's spirit and dedication, ensuring it remains at the forefront of the industry for years to come.
About Allison
Allison is a global integrated marketing and communications consultancy, dedicated to driving growth, innovation, and positive change for clients, colleagues, and communities. With a diverse range of expertise and a forward-looking mindset, Allison delivers game-changing results that make a lasting impact. Allison is owned by Stagwell (NASDAQ: STGW), one of the fastest growing and most influential marketing and communications networks in the world. Agency partners leverage Stagwell’s technology, data analytics, insights and strategic consulting solutions to drive measurable results and optimize return on marketing investment for more than 1,700 clients worldwide. Learn more at www.allisonworldwide.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906224146/en/
Contact information
For media inquiries:
Shanna Brown
Shanna.Brown@allisonworldwide.com
646.428.6837
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom